{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:24:20Z","timestamp":1786123460988,"version":"build-2736575974"},"reference-count":76,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.fjurol.2026.103139","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:39:40Z","timestamp":1780357180000},"page":"103139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond GnRH analogues: The renaissance of estrogens in prostate cancer management"],"prefix":"10.1016","volume":"36","author":[{"given":"Madalina","family":"Matthys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Roumegu\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bladou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.fjurol.2026.103139_bib0385","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrc801","article-title":"A history of prostate cancer treatment","volume":"2","author":"Denmeade","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.fjurol.2026.103139_bib0390","first-page":"232","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"22","author":"Huggins","year":"1972","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103139_bib0395","first-page":"1011","article-title":"Treatment and survival of patients with cancer of the prostate","volume":"124","year":"1967","journal-title":"Surg Gynecol Obstet"},{"issue":"8","key":"10.1016\/j.fjurol.2026.103139_bib0400","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nrendo.2016.70","article-title":"Control of puberty onset and fertility by gonadotropin-releasing hormone neurons","volume":"12","author":"Herbison","year":"2016","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103139_bib0405","first-page":"751","article-title":"Treatment of prostatic cancer: studies by the Veterans Administration cooperative urological research group","volume":"48","author":"Byar","year":"1972","journal-title":"Bull N Y Acad Med"},{"issue":"4","key":"10.1016\/j.fjurol.2026.103139_bib0410","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/pros.2990140410","article-title":"Estrogen therapy and liver function--metabolic effects of oral and parenteral administration","volume":"14","author":"von Schoultz","year":"1989","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.fjurol.2026.103139_bib0415","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/pcan.2009.35","article-title":"Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer","volume":"12","author":"Freedland","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"10.1016\/j.fjurol.2026.103139_bib0420","doi-asserted-by":"crossref","first-page":"bvae107","DOI":"10.1210\/jendso\/bvae107","article-title":"The loss of estradiol by androgen deprivation in prostate cancer patients shows the importance of estrogens in males","volume":"8","author":"Coelingh Bennink","year":"2024","journal-title":"J Endocr Soc"},{"issue":"27","key":"10.1016\/j.fjurol.2026.103139_bib0425","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.fjurol.2026.103139_bib0430","doi-asserted-by":"crossref","first-page":"e220182","DOI":"10.1530\/EC-22-0182","article-title":"Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review","volume":"11","author":"Coelingh Bennink","year":"2022","journal-title":"Endocr Connect"},{"issue":"3","key":"10.1016\/j.fjurol.2026.103139_bib0435","first-page":"649","article-title":"The role of estrogen in brain and cognitive aging","volume":"16","author":"Russell","year":"2019","journal-title":"Neurother J Am Soc Exp"},{"issue":"10274","key":"10.1016\/j.fjurol.2026.103139_bib0440","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(21)00100-8","article-title":"Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme","volume":"397","author":"Langley","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2026.103139_bib0445","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.euros.2021.04.005","article-title":"Estetrol cotreatment of androgen deprivation therapy in infiltrating or metastatic, castration-sensitive prostate cancer: a randomized, double-blind, phase II trial (PCombi)","volume":"28","author":"Coelingh Bennink","year":"2021","journal-title":"Eur Urol Open Sci"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103139_bib0450","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/bju.14153","article-title":"Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform","volume":"121","author":"Gilbert","year":"2018","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.fjurol.2026.103139_bib0455","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-22-0227","article-title":"Effects of estradiol on bone in men undergoing androgen deprivation therapy: a randomized placebo-controlled trial","volume":"187","author":"Russell","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.fjurol.2026.103139_bib0460","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1530\/EJE-18-1000","article-title":"MECHANISMS IN ENDOCRINOLOGY: estradiol as a male hormone","volume":"181","author":"Russell","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.fjurol.2026.103139_bib0465","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","article-title":"Estrogen receptor signaling mechanisms","volume":"116","author":"Fuentes","year":"2019","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"6","key":"10.1016\/j.fjurol.2026.103139_bib0470","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1210\/er.2014-1024","article-title":"Sex steroid actions in male bone","volume":"35","author":"Vanderschueren","year":"2014","journal-title":"Endocr Rev"},{"issue":"11","key":"10.1016\/j.fjurol.2026.103139_bib0475","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1206168","article-title":"Gonadal steroids and body composition, strength, and sexual function in men","volume":"369","author":"Finkelstein","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.fjurol.2026.103139_bib0480","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3390\/ijms22041568","article-title":"Critical role of estrogens on bone homeostasis in both male and female: from physiology to medical implications","volume":"22","author":"Emmanuelle","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.fjurol.2026.103139_bib0485","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1038\/s41467-023-40562-w","article-title":"Endothelial ER\u03b1 promotes glucose tolerance by enhancing endothelial insulin transport to skeletal muscle","volume":"14","author":"Sacharidou","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.fjurol.2026.103139_bib0490","doi-asserted-by":"crossref","first-page":"e1070","DOI":"10.1210\/clinem\/dgaf573","article-title":"Insulin sensitivity and associated plasma proteomics during sex hormone therapy","volume":"111","author":"van Eeghen","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.fjurol.2026.103139_bib0495","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2174\/1570159X15666170313122555","article-title":"Cognitive impacts of estrogen treatment in androgen-deprived males: what needs to be resolved","volume":"15","author":"Wibowo","year":"2017","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"10.1016\/j.fjurol.2026.103139_bib0500","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the women's health initiative randomized controlled trial","volume":"288","year":"2002","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103139_bib0505","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/cen.14689","article-title":"Effect of estradiol on cognition in men undergoing androgen deprivation therapy: a randomized placebo-controlled trial","volume":"97","author":"Russell","year":"2022","journal-title":"Clin Endocrinol"},{"issue":"9","key":"10.1016\/j.fjurol.2026.103139_bib0510","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1210\/jc.2016-1612","article-title":"Effects of testosterone and estradiol deficiency on vasomotor symptoms in hypogonadal men","volume":"101","author":"Taylor","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103139_bib0515","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/cen.14689","article-title":"Effect of estradiol on cognition in men undergoing androgen deprivation therapy: a randomized placebo-controlled trial","volume":"97","author":"Russell","year":"2022","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103139_bib0520","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","article-title":"The Xs and Y of immune responses to viral vaccines","volume":"10","author":"Klein","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.fjurol.2026.103139_bib0525","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2665-9913(23)00060-7","article-title":"The influence of sex hormones on musculoskeletal pain and osteoarthritis","volume":"5","author":"Gulati","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"4 Pt 1","key":"10.1016\/j.fjurol.2026.103139_bib0530","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.juro.2007.05.129","article-title":"Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy","volume":"178","author":"Morote","year":"2007","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2026.103139_bib0535","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","article-title":"Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations","volume":"22","author":"Crawford","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"10.1016\/j.fjurol.2026.103139_bib0540","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"issue":"8","key":"10.1016\/j.fjurol.2026.103139_bib0545","first-page":"CD012548","article-title":"Degarelix for treating advanced hormone-sensitive prostate cancer","volume":"8","author":"Zengerling","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"17","key":"10.1016\/j.fjurol.2026.103139_bib0550","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1001283","article-title":"Expression of follicle-stimulating hormone receptor in tumor blood vessels","volume":"363","author":"Radu","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.fjurol.2026.103139_bib0555","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/j.1464-410X.2013.11796.x","article-title":"Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs. antagonists: a matter of the receptors?","volume":"111","author":"Tolkach","year":"2013","journal-title":"BJU Int"},{"issue":"5\u20136","key":"10.1016\/j.fjurol.2026.103139_bib0560","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/21681805.2018.1522372","article-title":"FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist","volume":"52","author":"Crawford","year":"2018","journal-title":"Scand J Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2026.103139_bib0565","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(09)70338-9","article-title":"Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial","volume":"11","author":"Irani","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2026.103139_bib0570","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.euros.2025.06.010","article-title":"Re: Ruben Raychaudhuri, Daniel W. Lin, R. Bruce Montgomery. Prostate cancer: a review. JAMA 2025;333:1433-46","volume":"78","author":"Roldan-Testillano","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.fjurol.2026.103139_bib0575","doi-asserted-by":"crossref","DOI":"10.1038\/s41574-026-01247-8","article-title":"Neurokinin receptor antagonists for vasomotor symptoms: from KNDy neurons to clinical translation","author":"Torres","year":"2026","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"10.1016\/j.fjurol.2026.103139_bib0580","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s00198-013-2343-4","article-title":"Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D","volume":"24","author":"Alibhai","year":"2013","journal-title":"Osteoporos Int J Establ Result Coop Eur Found"},{"issue":"2","key":"10.1016\/j.fjurol.2026.103139_bib0585","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.fjurol.2026.103139_bib0590","doi-asserted-by":"crossref","first-page":"e225432","DOI":"10.1001\/jamanetworkopen.2022.5432","article-title":"Association of bone mineral density testing with risk of major osteoporotic fractures among older men receiving androgen deprivation therapy to treat localized or regional prostate cancer","volume":"5","author":"Suarez-Almazor","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.fjurol.2026.103139_bib0595","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(18)30047-0","article-title":"Bone health during endocrine therapy for cancer","volume":"6","author":"Rachner","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.fjurol.2026.103139_bib0600","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-026-01077-9","article-title":"Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis","author":"Saporita","year":"2026","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"10.1016\/j.fjurol.2026.103139_bib0605","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.4720","article-title":"The economic burden of severe osteoporotic fractures in the French Healthcare Database: the FRACTOS study","volume":"37","author":"Thomas","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.fjurol.2026.103139_bib0610","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00198-021-06189-7","article-title":"Costs of patient management over 18\u00a0months following a hip, clinical vertebral, distal forearm, or proximal humerus fragility fracture in France-results from the ICUROS study","volume":"33","author":"Coassy","year":"2022","journal-title":"Osteoporos Int J Establ Result Coop Eur Found"},{"issue":"3","key":"10.1016\/j.fjurol.2026.103139_bib0615","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5694\/mja2.51835","article-title":"Dual-energy X-ray absorptiometry assessment of bone health in Australian men with prostate cancer commencing androgen deprivation therapy","volume":"218","author":"Hamid","year":"2023","journal-title":"Med J Aust"},{"issue":"16_suppl","key":"10.1016\/j.fjurol.2026.103139_bib0620","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e24145","article-title":"Assessing our adherence to bone protection standards in metastatic prostate cancer in the largest Irish center: are we falling behind?","volume":"42","author":"Aslam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2026.103139_bib0625","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41391-021-00442-0","article-title":"Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis","volume":"25","author":"Lopez","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.fjurol.2026.103139_bib0630","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.fjurol.2026.103139_bib0635","doi-asserted-by":"crossref","first-page":"e13844","DOI":"10.1002\/jcsm.13844","article-title":"Androgen deprivation therapy-induced muscle loss and fat gain predict cardiovascular events in prostate cancer patients","volume":"16","author":"Lee","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.fjurol.2026.103139_bib0640","doi-asserted-by":"crossref","first-page":"104050","DOI":"10.1016\/j.clon.2026.104050","article-title":"The relationship between prostate cancer treatments and changes to musculature: a systematic review","author":"Partridge","year":"2026","journal-title":"Clin Oncol R Coll Radiol G B"},{"issue":"6","key":"10.1016\/j.fjurol.2026.103139_bib0645","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.juro.2014.12.086","article-title":"The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy","volume":"193","author":"Morote","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103139_bib0650","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3332\/ecancer.2018.802","article-title":"A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus","volume":"12","author":"Crawley","year":"2018","journal-title":"Ecancermedicalscience"},{"issue":"12","key":"10.1016\/j.fjurol.2026.103139_bib0655","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/ijc.30403","article-title":"Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer","volume":"139","author":"Crawley","year":"2016","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.fjurol.2026.103139_bib0660","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103139_bib0665","first-page":"e255586","article-title":"Coronary plaque progression after androgen deprivation therapy in men with prostate cancer: a randomized clinical trial","author":"Patel","year":"2026","journal-title":"JAMA Cardiol"},{"issue":"23","key":"10.1016\/j.fjurol.2026.103139_bib0670","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103139_bib0675","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.urolonc.2017.01.025","article-title":"The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy","volume":"35","author":"Crawford","year":"2017","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2026.103139_bib0680","doi-asserted-by":"crossref","first-page":"307e1","DOI":"10.1016\/j.jpainsymman.2017.09.017","article-title":"Effects of androgen deprivation therapy on pain perception, quality of life, and depression in men with prostate cancer","volume":"55","author":"Gagliano-Juc\u00e1","year":"2018","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"10.1016\/j.fjurol.2026.103139_bib0685","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/annonc\/mdx744","article-title":"Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer","volume":"29","author":"Yang","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.fjurol.2026.103139_bib0690","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3390\/jcm11072039","article-title":"Association between androgen deprivation therapy and the risk of inflammatory rheumatic diseases in men with prostate cancer: nationwide cohort study in Lithuania","volume":"11","author":"Drevinskaite","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.fjurol.2026.103139_bib0695","article-title":"Cognitive impairment among prostate cancer patients: an overview of reviews","volume":"26","author":"Treanor","year":"2017","journal-title":"Eur J Cancer Care"},{"issue":"12","key":"10.1016\/j.fjurol.2026.103139_bib0700","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.35210","article-title":"Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis","volume":"130","author":"Bou\u00e9","year":"2024","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.fjurol.2026.103139_bib0705","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(18)30780-0","article-title":"Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study","volume":"20","author":"Downing","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.fjurol.2026.103139_bib0710","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/pros.24676","article-title":"Development of depression in patients using androgen deprivation therapy: a systemic review and meta-analysis","volume":"84","author":"Qazi","year":"2024","journal-title":"Prostate"},{"issue":"11","key":"10.1016\/j.fjurol.2026.103139_bib0715","first-page":"3835","article-title":"Mood, sexuality, and relational intimacy after starting androgen deprivation therapy: implications for couples","volume":"26","author":"Walker","year":"2018","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103139_bib0720","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ejca.2013.11.034","article-title":"Patients\u2019 self-assessment versus investigators\u2019 evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)","volume":"50","author":"Gravis","year":"2014","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.fjurol.2026.103139_bib0725","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/bju.70022","article-title":"Patient-reported outcome measures in prostate research: a scoping review","volume":"137","author":"Young","year":"2026","journal-title":"BJU Int"},{"issue":"16","key":"10.1016\/j.fjurol.2026.103139_bib0730","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa2511781","article-title":"Transdermal estradiol patches in locally advanced prostate cancer","volume":"394","author":"Langley","year":"2026","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103139_bib0735","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bju.13687","article-title":"Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer","volume":"119","author":"Gilbert","year":"2017","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103139_bib0740","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1530\/EJE-17-1072","article-title":"Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial","volume":"178","author":"Russell","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103139_bib0745","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1530\/EJE-22-0318","article-title":"Effects of oestradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial","volume":"187","author":"Russell","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.fjurol.2026.103139_bib0750","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/GME.0000000000002537","article-title":"The rediscovery of estetrol and its implications for estrogen treatment","volume":"32","author":"Coelingh Bennink","year":"2025","journal-title":"Menopause"},{"key":"10.1016\/j.fjurol.2026.103139_bib0755","article-title":"Navigating drug-drug interactions with apalutamide","author":"Siddiqui","year":"2026","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.fjurol.2026.103139_bib0760","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/1471-0528.16840","article-title":"Estetrol-drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia","volume":"129","author":"Gemzell-Danielsson","year":"2022","journal-title":"BJOG Int J Obstet Gynaecol"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026000707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026000707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:36:01Z","timestamp":1786113361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393026000707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":76,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950393026000707"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103139","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond GnRH analogues: The renaissance of estrogens in prostate cancer management","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103139"}}